# US Brucellosis Market

> US Brucellosis Market Research Report: By species (Brucella suis, B. abortus, B. melitensis) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.97%
- **2024:** $ 138.09 Million
- **2025:** $ 147.71 Million
- **2035:** $ 289.81 Million
- **Key Players:** Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol SA (FR), Elanco Animal Health (US)

**Report ID:** MRFR/LS/18051-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-brucellosis-market-19598

---

## Market Summary

## **US Brucellosis Market Overview**

As per MRFR analysis, the US Brucellosis Market Size was estimated at 59.78 (USD Million) in 2023. The US Brucellosis Market Industry is expected to grow from 65.1 (USD Million) in 2024 to 141 (USD Million) by 2035. The US Brucellosis Market CAGR (growth rate) is expected to be around 7.278% during the forecast period (2025 - 2035).

### **Key Trends in the US Brucellosis Market**

The US Brucellosis Market is witnessing significant trends driven by changes in industry practices and public health awareness. Increasing cases of brucellosis among livestock have heightened concerns about food safety and public health, leading to government initiatives focused on disease control and prevention. Regulatory frameworks along with stringent monitoring mechanisms are being implemented to manage brucellosis in cattle and farm animals effectively.

This regulatory attention acts as a key market driver, as both farmers and industry stakeholders are motivated to adopt preventive measures and vaccination programs to mitigate the economic losses associated with outbreaks. Additionally, heightened awareness related to zoonotic diseases is creating opportunities in the market. As consumers become more health-conscious, there is a growing demand for brucellosis-free meat and dairy products, which encourages producers to adopt more rigorous health standards.

The increased emphasis on biosecurity measures on farms provides a pivotal opportunity for the development of vaccines and diagnostic kits aimed specifically at brucellosis prevention. Recent trends show that advancements in veterinary diagnostics are leading to better disease management and control strategies. The use of modern technology like molecular diagnostics and automation in laboratories is improving the speed and accuracy of brucellosis testing.

Subsequently, educational programs aimed at farmers regarding brucellosis prevention are gaining traction, bolstering community engagement and reinforcing best practices in animal husbandry. This combination of scientific advancement and community awareness is expected to shape the future landscape of the US Brucellosis Market, aligning with broader public health goals and livestock management strategies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Brucellosis Market Drivers**

### **Increasing Incidence of Brucellosis in Livestock**

The rising incidence of Brucellosis in livestock, particularly cattle and buffaloes, is a significant driver for the US [Brucellosis Market](../../../reports/brucellosis-market-5159) Industry. According to the United States Department of Agriculture (USDA), there were over 100 reported cases of Brucellosis in bovine cattle in the past year alone. This prevalent occurrence necessitates increased monitoring and control measures, leading to an uptick in demand for diagnostic tests and vaccines.

Organizations like the American Veterinary Medical Association are actively involved in researching effective means to manage this disease, which impacts livestock health, consequently influencing the growth of the US Brucellosis Market Industry as farmers and veterinarians seek better solutions for prevention and treatment.

### **Government Initiatives and Funding for Disease Control**

The US government has ramped up its efforts to control and eradicate Brucellosis, particularly in livestock, through various initiatives and funding programs. The USDA has allocated millions in grants specifically aimed at improving herd management and disease prevention strategies. These initiatives provide financial support for Research and Development (R&D) of new vaccines and diagnostic tools, contributing to market growth.

With the USDA reporting an increase in funding by 15% over the last five years for programs targeting livestock diseases, the US Brucellosis Market Industry is well-positioned to benefit from these increased investments, as they stimulate advancements in treatment methods and preventive measures.

### **Growth in Animal Health Awareness**

There is a growing awareness regarding animal health in the US, including the implications of Brucellosis not just on livestock, but also on public health. Education campaigns led by organizations such as the Centers for Disease Control and Prevention (CDC) have highlighted the zoonotic nature of Brucellosis, where the disease can transfer from animals to humans, leading to flu-like symptoms and more severe complications.

This awareness has spurred farmers and ranchers to prioritize better health practices and vaccinations for their herds, driving demand within the US Brucellosis Market Industry. The CDC has noted an increase in requests for health-related workshops and training related to animal diseases, indicating a trend that can be leveraged for stronger market growth.

## **US Brucellosis Market Segment Insights**

### **Brucellosis Market species Insights**

The US Brucellosis Market exhibits a diverse segmentation based on species, each contributing distinctly to the overall dynamics of the industry. This segment includes Brucella suis, B. abortus, and B. melitensis, with each species relating to different host animals and associated pathology. B. abortus, primarily affecting cattle, is crucial in terms of livestock disease management, as its presence can significantly impact agricultural productivity and consequently the agricultural economy in the US.

The management of this species is vital for ensuring food safety and protecting public health, since cattle are a major source of livestock products consumed nationwide. B. melitensis, affecting sheep and goats, is significant as it poses risks not only to livestock health but also to human populations, particularly in individuals who engage in direct contact with infected animals or contaminated products.

This aspect elevates the importance of rigorous monitoring and control measures within the agricultural protocols. Lastly, Brucella suis, which primarily impacts swine, is notable not just for its effects on animal health but also for its implications on the broader meat market; controlling this strain is essential in maintaining the health of swine populations, which are pivotal in the US meat supply chain.

The understanding of these species and their unique characteristics informs research and development focused on vaccines and diagnostics, ultimately aiming to reduce the economic burden associated with brucellosis. Overall, the interplay between these species and their management strategies significantly influences market trends and presents opportunities for advancements in veterinary science, public health initiatives, and agricultural practices.

As health agencies and agricultural organizations continue to address brucellosis, the species-based segmentation remains a focal point in efforts to mitigate infectious diseases in both animals and humans across the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Brucellosis Market Key Players and Competitive Insights**

The competitive insights of the US Brucellosis Market reveal a landscape shaped by various players offering specialized solutions aimed at combating this zoonotic disease that affects livestock and can pose risks to human health. The market has been experiencing innovation in terms of diagnostic tools, vaccines, and therapeutic agents, catering to both animal health and food security concerns.

Competitive strategies among key participants encompass product differentiation, technological advancement, strategic alliances, and strong delivery networks. Companies consistently strive to secure a more substantial market share through ongoing research and development efforts, alongside collaborations with agricultural stakeholders to enhance the effectiveness of prevention and control measures against brucellosis.

Such dynamics create a robust environment where product efficacy, regulatory compliance, and market accessibility become crucial factors influencing competitive positioning. Elanco stands out within the US Brucellosis Market with a solid portfolio of products focused on animal health, particularly in the prevention and treatment of brucellosis in livestock.

Its commitment to research and development has enabled the company to deliver effective solutions tailored for veterinarians and farm operators seeking to manage and mitigate the risks associated with brucellosis. Elanco's established presence in the animal health sector is bolstered by its extensive distribution networks and strategic partnerships with veterinary professionals and organizations, ensuring that they remain a reliable source for effective brucellosis management solutions.

By leveraging its strengths in innovation and customer support, Elanco continues to maintain a competitive edge while effectively addressing the challenges posed by this disease in the US agricultural landscape. Vetoquinol is also a significant player in the US Brucellosis Market, providing a range of veterinary pharmaceuticals and vaccines specifically designed to combat this bovine disease.

The company's strengths lie in its commitment to quality and the development of effective health products, which cater to the specific needs of livestock producers. Vetoquinol's market presence is characterized by strong relationships with veterinarians and a deep understanding of the regulatory environment surrounding animal health in the US.

Their key products include vaccines that serve as a crucial line of defense against brucellosis, reinforcing animal health and farm productivity. Recently, Vetoquinol has pursued strategic mergers and acquisitions to enhance its product offerings and expand its operational capabilities.

These moves not only bolster their market position but also position Vetoquinol as a formidable competitor in addressing brucellosis through continuous innovation and a focused approach to customer needs within the animal health sector in the US.

### **Key Companies in the US Brucellosis Market Include**

## **US Brucellosis Market Industry Developments**

Recent developments in the US Brucellosis Market indicate a growing focus on vaccination and prevention strategies to combat this zoonotic disease, primarily in cattle and bison herds. Companies such as Elanco, Zoetis, and Merck Animal Health are actively enhancing their vaccination offerings and developing more effective diagnostic tools to reduce Brucellosis prevalence.

In recent months, additional investment in Research and Development has been noted, particularly by Vetoquinol and Heska, reflecting a broader industry trend towards innovation in livestock health management. Noteworthy happenings include a significant rise in market valuation driven by increased demand for animal health products, revealing a compound annual growth rate that highlights the market's robust expansion.

In terms of mergers and acquisitions, no recent activities involving the specified companies have been reported, yet the market remains dynamic with various strategic collaborations anticipated. Over the last few years, the USDA has emphasized eradication efforts, strengthening regulatory frameworks to ensure the reduction of Brucellosis incidences.

The collective efforts of these companies, together with governmental initiatives, underscore the importance of maintaining animal health and addressing public health concerns associated with Brucellosis in the US.

## **US Brucellosis Market Segmentation Insights**

### **Brucellosis Market species Outlook**

## Market Drivers

### Increased Focus on Animal Health

The growing emphasis on animal health and welfare is a notable driver for the brucellosis market. As livestock producers and veterinarians recognize the economic implications of brucellosis outbreaks, there is a heightened focus on preventive measures. This includes regular screening, vaccination, and biosecurity protocols to mitigate the risk of disease transmission. The economic impact of brucellosis on livestock productivity can be substantial, leading to losses in milk and meat production. Consequently, stakeholders in the agricultural sector are likely to invest in brucellosis management solutions, thereby driving market growth. The intersection of animal health initiatives and public health concerns further underscores the importance of addressing brucellosis, positioning the market for continued expansion.

### Government Initiatives and Funding

Government initiatives aimed at controlling and preventing brucellosis outbreaks significantly influence the brucellosis market. Federal and state agencies are increasingly allocating funds for research, surveillance, and vaccination programs. For instance, the USDA has implemented various programs to support livestock vaccination and disease management, which directly impacts the market. The financial backing from government sources not only enhances the development of new diagnostic tools and treatments but also encourages collaboration between public health entities and private sector stakeholders. This synergy is likely to lead to innovative solutions that address the challenges posed by brucellosis. As funding continues to flow into this sector, the brucellosis market is expected to experience robust growth, driven by the need for effective disease control measures.

### Rising Demand for Diagnostic Testing

The increasing demand for accurate and rapid diagnostic testing for brucellosis is a crucial driver for the brucellosis market. As awareness of the disease grows among healthcare professionals and the public, the need for reliable diagnostic tools becomes more pronounced. The market for diagnostic tests, including serological assays and molecular techniques, is expanding as healthcare providers seek to improve disease detection and management. The CDC emphasizes the importance of timely diagnosis in controlling brucellosis outbreaks, which further fuels the demand for innovative testing solutions. With advancements in diagnostic technology, the brucellosis market is likely to witness significant growth, driven by the need for effective disease surveillance and management strategies.

### Rising Incidence of Brucellosis Cases

The increasing incidence of brucellosis cases in the US is a critical driver for the brucellosis market. Reports indicate that the number of reported cases has seen a rise, particularly in regions with high livestock populations. This uptick in cases necessitates enhanced diagnostic and treatment options, thereby propelling market growth. The Centers for Disease Control and Prevention (CDC) has noted that brucellosis remains a concern for public health, especially among individuals working in agriculture and animal husbandry. As awareness of the disease's impact grows, healthcare providers are likely to invest more in brucellosis-related products and services, further stimulating the market. The economic burden associated with brucellosis, estimated at millions of dollars annually, underscores the need for effective management strategies, which in turn supports the expansion of the brucellosis market.

### Technological Innovations in Treatment

Technological advancements in treatment options for brucellosis are emerging as a significant driver for the brucellosis market. Recent developments in antibiotic therapies and vaccine formulations have shown promise in effectively managing the disease. The introduction of novel therapeutic agents that target the bacteria responsible for brucellosis could potentially reduce treatment duration and improve patient outcomes. Furthermore, the integration of technology in vaccine delivery systems, such as needle-free devices, may enhance vaccination rates among at-risk populations. As healthcare providers seek more effective and efficient treatment modalities, the demand for innovative solutions is likely to rise. This trend suggests a dynamic shift in the brucellosis market, where technological innovations play a pivotal role in shaping future treatment landscapes.

## Future Outlook

The [Brucellosis Market](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) is projected to grow at a 6.97% CAGR from 2025 to 2035, driven by advancements in diagnostics, increased awareness, and enhanced vaccination programs.

**New opportunities:**

- Development of rapid diagnostic kits for field use
- Expansion of telemedicine services for remote consultations
- Investment in vaccine research for livestock and wildlife

By 2035, the brucellosis market is expected to achieve robust growth and enhanced market stability.

## Segment Insights

### By Species: Brucella abortus (Largest) vs. Brucella canis (Fastest-Growing)

In the US brucellosis market, the species segments showcase varied market share distributions. The dominant player, Brucella abortus, holds a significant portion of the market, largely due to its prevalence in cattle and its historical impact on livestock health. Following it, Brucella suis and Brucella melitensis contribute to a lesser extent, with Brucella canis emerging as a noteworthy segment due to increasing awareness and incidences of canine brucellosis. The segment categorized as 'others' consists of less common species that account for a small fraction of the market.

Growth trends in the US brucellosis market are greatly influenced by heightened veterinary awareness and the push for eradication programs against specific strains, particularly Brucella canis. This segment is recognized as the fastest-growing, attributed to rising incidences among dogs and subsequent demand for diagnostic tests and vaccines. As veterinarians and pet owners become more conscious of the risks associated with brucellosis, investment in research and better methods for detection is also expected to drive significant advancements in the market.

Brucella abortus (Dominant) vs. Brucella canis (Emerging)

Brucella abortus remains the dominant species in the US brucellosis market due to its strong association with cattle infections, which have severe implications for livestock productivity and public health. Its longstanding presence in the environment and livestock sectors solidifies its stronghold. In contrast, Brucella canis is emerging rapidly as a significant focus, largely driven by increasing awareness of its impact on companion animals. This rise can be linked to an uptick in diagnostic activities and preventive health measures for dogs. Moving forward, there is an anticipated increase in investment and research focused on Brucella canis, as veterinary professionals strive to better understand and manage this infection among pets, marking it as a noteworthy segment in the overall landscape of the market.

### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing)

In the US brucellosis market, the diagnosis segment is characterized by diverse methodologies including serological tests, molecular techniques, bone marrow biopsy, X-rays, and advanced imaging such as CT and MRI. Among these, serological tests command the largest market share due to their established efficacy and wide acceptance in clinical settings. Meanwhile, molecular techniques are rapidly gaining traction, contributing to significant shifts in the overall market dynamics.

Growth in this segment is driven by advancements in diagnostic technologies, with increasing demand for rapid and accurate testing solutions. The rise of molecular techniques, particularly PCR-based methods, is fueled by their ability to deliver results faster than traditional methods, catering to the urgency in clinical diagnostics. Furthermore, the integration of imaging techniques is enhancing diagnostic precision, making it a pivotal area for innovation and investment within the market.

Serological Tests (Dominant) vs. Molecular Techniques (Emerging)

Serological tests have long been the cornerstone of brucellosis diagnosis, leveraging established methodologies to deliver reliable results. Their dominance is attributed to their accessibility and cost-effectiveness, making them the preferred choice for many healthcare professionals. In contrast, molecular techniques, while emerging, are reshaping the diagnostics landscape due to their rapidity and accuracy. PCR and other advanced diagnostic tools are increasingly adopted, catering to the growing need for timely interventions in brucellosis management. As these technology-driven approaches continue to evolve, their market position strengthens, intensifying competition within the segment. The distinction in their operational characteristics—serological tests focusing on antibody detection and molecular techniques on pathogen identification—further delineates their roles in comprehensive brucellosis diagnosis.

### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing)

In the US brucellosis market, the treatment segment is primarily dominated by antibiotics, which hold the largest market share due to their established efficacy in combating the infection. Vaccines are gaining traction, representing a significant emerging force in the landscape, but their share currently lags behind that of antibiotics. Other treatment modalities contribute to a smaller fraction of the market but are steadily increasing in relevance as comprehensive treatment strategies develop.

Growth trends in this segment show a robust increase in the demand for vaccines, driven by heightened awareness and preventive healthcare measures. The push for safer alternatives to antibiotic therapy is prompting innovations in vaccine development, positioning them as the fastest-growing category. Additionally, the changing regulatory landscape and supportive government policies are further enhancing overall market dynamics, encouraging research and development in treatment options.

Antibiotics (Dominant) vs. Vaccines (Emerging)

The antibiotics segment remains dominant in the treatment of brucellosis, due to its historical efficacy and familiarity among healthcare providers. These pharmaceuticals are widely used and have established protocols that support their use in treatment. Conversely, vaccines represent an emerging segment, with advancements in technology leading to more effective immunological responses against brucellosis. As stakeholder awareness increases and investment in research grows, vaccines are seeing accelerated adoption across various sectors, particularly in livestock management. The integration of these treatments reflects the evolving strategies in disease management, with a significant shift towards preventive methodologies to complement antibiotic use.

### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Pharmaceutical & Biotechnology Companies (Fastest-Growing)

In the US brucellosis market, the end-user segment is primarily dominated by hospitals and diagnostic centers, which capture a sizable share due to their critical role in disease diagnosis and management. Academic institutes, while important for research, hold a smaller portion of the market. Pharmaceutical and biotechnology companies follow closely, leveraging advancements in diagnostic technologies and therapeutics to bolster their positions in the market.

Growth trends indicate that the demand for brucellosis testing and treatment options is rising, driven by increased awareness and the need for rapid diagnostic solutions. Pharmaceutical and biotechnology companies are experiencing the fastest growth, mainly due to innovation in brucellosis products. Collaborations among academic institutions and hospitals are expected to further enhance research and development, fueling market expansion in the coming years.

Hospitals & Diagnostic Centers (Dominant) vs. Academic Institutes (Emerging)

Hospitals and diagnostic centers play a dominant role in the US brucellosis market, characterized by their ability to provide essential diagnostics and treatment facilities. These institutions are equipped with advanced technologies that facilitate effective brucellosis detection and management, making them vital in the healthcare landscape. In contrast, academic institutes, while emerging in this field, primarily focus on research and development, striving to understand disease dynamics and develop innovative diagnostic methods. Though they currently occupy a smaller share, their contribution to educational initiatives and studies is critical for the future growth of the market, fostering partnerships that may enhance overall health outcomes.

## Competitive Benchmarking

The brucellosis market exhibits a competitive landscape characterized by a blend of established players and emerging innovators. Key growth drivers include increasing awareness of zoonotic diseases, advancements in diagnostic technologies, and a rising demand for effective vaccines. Major companies such as Zoetis Inc (US), Merck & Co Inc (US), and Elanco Animal Health (US) are strategically positioned to leverage these trends. Zoetis Inc (US) focuses on innovation in vaccine development, while Merck & Co Inc (US) emphasizes partnerships to enhance its product portfolio. Elanco Animal Health (US) is actively pursuing regional expansion to tap into underserved markets, collectively shaping a dynamic competitive environment.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains. This strategy not only enhances operational efficiency but also allows companies to respond swiftly to regional demands. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic collaborations are paramount.

In October  Zoetis Inc (US) announced the launch of a new brucellosis vaccine aimed at improving herd immunity in cattle. This strategic move is significant as it addresses the growing concerns regarding livestock health and food safety, potentially positioning Zoetis as a leader in the vaccine segment. The introduction of this vaccine could enhance their market share and reinforce their commitment to animal health.

In September  Merck & Co Inc (US) entered a strategic partnership with a leading agricultural technology firm to develop advanced diagnostic tools for brucellosis detection. This collaboration is likely to enhance Merck's capabilities in providing comprehensive solutions for livestock management, thereby strengthening its competitive edge. The integration of cutting-edge technology into their offerings may also lead to improved customer satisfaction and loyalty.

In August  Elanco Animal Health (US) expanded its operations into the Midwest region, focusing on increasing access to its brucellosis management solutions. This expansion is crucial as it allows Elanco to cater to a larger customer base, particularly in areas with high livestock density. By enhancing its regional presence, Elanco is poised to capture additional market share and respond more effectively to local needs.

As of November  current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and customer engagement. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of agility and responsiveness in meeting the evolving demands of the brucellosis market.

## Recent News & Developments

Recent developments in the US Brucellosis Market indicate a growing focus on vaccination and prevention strategies to combat this zoonotic disease, primarily in cattle and bison herds. Companies such as Elanco, Zoetis, and Merck Animal Health are actively enhancing their vaccination offerings and developing more effective diagnostic tools to reduce Brucellosis prevalence.

In recent months, additional investment in Research and Development has been noted, particularly by Vetoquinol and Heska, reflecting a broader industry trend towards innovation in livestock health management. Noteworthy happenings include a significant rise in market valuation driven by increased demand for animal health products, revealing a compound annual growth rate that highlights the market's robust expansion.

In terms of mergers and acquisitions, no recent activities involving the specified companies have been reported, yet the market remains dynamic with various strategic collaborations anticipated. Over the last few years, the USDA has emphasized eradication efforts, strengthening regulatory frameworks to ensure the reduction of Brucellosis incidences.

The collective efforts of these companies, together with governmental initiatives, underscore the importance of maintaining animal health and addressing public health concerns associated with Brucellosis in the US.

## Report Scope

| MARKET SIZE 2024 | 138.09(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 147.71(USD Million) |
| MARKET SIZE 2035 | 289.81(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.97% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol SA (FR), Elanco Animal Health (US) |
| Segments Covered | Species, Diagnosis, Treatment, End-User |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the brucellosis market. |
| Key Market Dynamics | Rising regulatory scrutiny and advancements in diagnostic technologies are reshaping the brucellosis market landscape. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US brucellosis market in 2024?**
A: The US brucellosis market was valued at 138.09 USD Million in 2024.

**Q: What is the projected market valuation for the US brucellosis market by 2035?**
A: The projected valuation for the US brucellosis market is 289.81 USD Million by 2035.

**Q: What is the expected CAGR for the US brucellosis market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US brucellosis market during the forecast period 2025 - 2035 is 6.97%.

**Q: Which companies are the key players in the US brucellosis market?**
A: Key players in the US brucellosis market include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim, Ceva Santé Animale, Virbac, Heska Corporation, Vetoquinol SA, and Elanco Animal Health.

**Q: What are the main segments of the US brucellosis market?**
A: The main segments of the US brucellosis market include species, diagnosis, treatment, and end-user.

**Q: What was the market valuation for Brucella abortus in 2024?**
A: The market valuation for Brucella abortus was between 30.0 and 60.0 USD Million in 2024.

**Q: How much is the market for antibiotics projected to grow in the treatment segment?**
A: The market for antibiotics in the treatment segment is projected to range from 40.0 to 80.0 USD Million.

**Q: What is the valuation range for serological tests in the diagnosis segment?**
A: The valuation range for serological tests in the diagnosis segment was between 20.0 and 40.0 USD Million.

**Q: Which end-user segment is expected to have the highest valuation in 2024?**
A: The pharmaceutical & biotechnology companies segment is expected to have the highest valuation, ranging from 50.0 to 100.0 USD Million.

**Q: What is the projected growth for the Brucella canis segment by 2035?**
A: The Brucella canis segment is projected to grow, with a valuation range of 15.0 to 30.0 USD Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-brucellosis-market-19598*